CN105188725B - 靶向真菌细胞壁多糖的抗体 - Google Patents

靶向真菌细胞壁多糖的抗体 Download PDF

Info

Publication number
CN105188725B
CN105188725B CN201480026536.9A CN201480026536A CN105188725B CN 105188725 B CN105188725 B CN 105188725B CN 201480026536 A CN201480026536 A CN 201480026536A CN 105188725 B CN105188725 B CN 105188725B
Authority
CN
China
Prior art keywords
compound
chitin
fungal
vaccine
glucan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480026536.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105188725A (zh
Inventor
F·米琼
F·卡梅尔
K·雷恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Vaccines LLC
Original Assignee
Wellstat Vaccines LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Vaccines LLC filed Critical Wellstat Vaccines LLC
Publication of CN105188725A publication Critical patent/CN105188725A/zh
Application granted granted Critical
Publication of CN105188725B publication Critical patent/CN105188725B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
CN201480026536.9A 2013-03-12 2014-03-06 靶向真菌细胞壁多糖的抗体 Expired - Fee Related CN105188725B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361777631P 2013-03-12 2013-03-12
US61/777,631 2013-03-12
PCT/US2014/021128 WO2014158963A1 (en) 2013-03-12 2014-03-06 Antibodies targeted to fungal cell wall polysaccharides

Publications (2)

Publication Number Publication Date
CN105188725A CN105188725A (zh) 2015-12-23
CN105188725B true CN105188725B (zh) 2020-08-21

Family

ID=51625093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026536.9A Expired - Fee Related CN105188725B (zh) 2013-03-12 2014-03-06 靶向真菌细胞壁多糖的抗体

Country Status (10)

Country Link
US (6) US20160017062A1 (enExample)
EP (1) EP2968427B1 (enExample)
JP (2) JP6434958B2 (enExample)
CN (1) CN105188725B (enExample)
AU (1) AU2014241492A1 (enExample)
DK (1) DK2968427T3 (enExample)
ES (1) ES2936811T3 (enExample)
FI (1) FI2968427T3 (enExample)
PL (1) PL2968427T3 (enExample)
WO (1) WO2014158963A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014158963A1 (en) 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
CN111707815A (zh) * 2019-12-31 2020-09-25 安徽中医药大学 一种通过白色念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
CN113274489B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种预防真菌感染的几丁质寡糖疫苗及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312908A (en) * 1989-08-29 1994-05-17 Tamatsukuri Corporation Chitin-chitosan oligomer having 2,5-amhydromannitol group or 2,5-anhydromannose group at terminal end and method for preparation thereof
WO2003042250A1 (en) * 2001-11-15 2003-05-22 Biosyntech Canada Inc. Composition and method to homogeneously modify or cross-link chitosan under neutral conditions
US6602508B2 (en) * 1995-06-07 2003-08-05 Baxter International Inc. Method of immunization using a Group B Streptococcus type II and type III polysaccharide conjugate vaccine
WO2006096970A1 (en) * 2005-03-14 2006-09-21 Governors Of The University Of Alberta Synthetic anti-candida albicans oligosaccharide based vaccines
US20090232831A1 (en) * 2008-03-13 2009-09-17 Chi-Huey Wong Methods and compositions for the treatment or prevention of human immunodeficiency virus infection
WO2010015022A1 (en) * 2008-08-05 2010-02-11 The University Of Queensland Antigen-presenting scaffolds
US7824688B2 (en) * 2002-05-15 2010-11-02 Antonio Cassone Glucan-based vaccines
WO2011080595A2 (en) * 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62138496A (ja) 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
JP2868635B2 (ja) * 1991-02-25 1999-03-10 玉造株式会社 キチン・キトサンオリゴマーの精製方法
JP2786389B2 (ja) * 1993-05-18 1998-08-13 玉造株式会社 腫瘍免疫治療剤
US5705634A (en) 1995-03-02 1998-01-06 Perimmune Holdings, Inc. High yield preparation of dimeric to decameric chitin oligomers
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
HUE035956T2 (en) 2005-06-14 2018-05-28 Genis Hf Preparations of partially deacetylated chitin derivatives
KR100793756B1 (ko) * 2006-08-07 2008-01-10 엘지전자 주식회사 녹화 목록 표시 방법 및 그 장치
US20080311595A1 (en) 2007-06-18 2008-12-18 Inger Mattsby-Baltzer Rapid fungal detection assay and product
EP2123261A1 (en) 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
JP5555230B2 (ja) 2008-07-21 2014-07-23 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド β−１，６−グルコサミンオリゴ糖を合成するための方法および組成物
US20110223195A1 (en) 2008-09-05 2011-09-15 Ceva Sante Animale Sa Composition comprising chitosan for ocular administration of vaccine(s) to avians
AU2009307693B2 (en) * 2008-10-23 2016-04-14 The Lubrizol Corporation Lubricating composition containing metal carboxylate
JP5617127B2 (ja) * 2009-05-08 2014-11-05 大石　哲也 新規グアナミン化合物、その誘導体及びそれらの製造方法
JP2012241084A (ja) * 2011-05-18 2012-12-10 Nippon Terupen Kagaku Kk バインダー樹脂用溶剤
WO2014158963A1 (en) * 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312908A (en) * 1989-08-29 1994-05-17 Tamatsukuri Corporation Chitin-chitosan oligomer having 2,5-amhydromannitol group or 2,5-anhydromannose group at terminal end and method for preparation thereof
US6602508B2 (en) * 1995-06-07 2003-08-05 Baxter International Inc. Method of immunization using a Group B Streptococcus type II and type III polysaccharide conjugate vaccine
WO2003042250A1 (en) * 2001-11-15 2003-05-22 Biosyntech Canada Inc. Composition and method to homogeneously modify or cross-link chitosan under neutral conditions
US7824688B2 (en) * 2002-05-15 2010-11-02 Antonio Cassone Glucan-based vaccines
WO2006096970A1 (en) * 2005-03-14 2006-09-21 Governors Of The University Of Alberta Synthetic anti-candida albicans oligosaccharide based vaccines
US20090232831A1 (en) * 2008-03-13 2009-09-17 Chi-Huey Wong Methods and compositions for the treatment or prevention of human immunodeficiency virus infection
WO2010015022A1 (en) * 2008-08-05 2010-02-11 The University Of Queensland Antigen-presenting scaffolds
WO2011080595A2 (en) * 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Preparation and development of anti chitosan antibodies;Pierre Sorlier等;《Journal of biomedical materials reasearch》;20031201;第67卷(第3期);第766-774页 *
甲壳素及其衍生物壳聚糖的药理作用和临床应用研究进展;倪天庆等;《现代药物与临床》;20120531;第27卷(第3期);第313-316页 *

Also Published As

Publication number Publication date
US10752704B2 (en) 2020-08-25
FI2968427T3 (fi) 2023-03-01
US10519253B2 (en) 2019-12-31
EP2968427A4 (en) 2016-08-31
EP2968427A1 (en) 2016-01-20
DK2968427T3 (da) 2023-01-30
US10988552B2 (en) 2021-04-27
JP2018172696A (ja) 2018-11-08
ES2936811T3 (es) 2023-03-22
US20200339707A1 (en) 2020-10-29
EP2968427B1 (en) 2022-10-26
PL2968427T3 (pl) 2023-02-27
US20180251573A1 (en) 2018-09-06
JP6434958B2 (ja) 2018-12-05
JP2016513747A (ja) 2016-05-16
US20210301037A1 (en) 2021-09-30
HK1220360A1 (en) 2017-05-05
US10259888B2 (en) 2019-04-16
US20190169315A1 (en) 2019-06-06
WO2014158963A1 (en) 2014-10-02
US20200062866A1 (en) 2020-02-27
CN105188725A (zh) 2015-12-23
US20160017062A1 (en) 2016-01-21
AU2014241492A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
Cutler et al. Advances in combating fungal diseases: vaccines on the threshold
US10988552B2 (en) Antibodies targeted to fungal cell wall polysaccharides
CN104080479B (zh) 包括spr0096和spr2021抗原的运载体分子
JP7036854B2 (ja) シクロアルキン誘導体化糖類
CN108064174A (zh) 抗原的载体分子
Khatun et al. Immunogenicity assessment of cell wall carbohydrates of Group A Streptococcus via self-adjuvanted glyco-lipopeptides
ES2869181T3 (es) Métodos y preparaciones de beta-glucano opsonizado
Feng et al. Exploration of recombinant fusion proteins YAPO and YAPL as carrier proteins for glycoconjugate vaccine design against Streptococcus pneumoniae infection
HK1220360B (en) Conjugate for inducing antibodies targeting fungal cell wall polysaccharides
AT525943B1 (de) Konjugat bestehend aus oder umfassend zumindest ein β-Glucan oder ein Mannan
US20250186596A1 (en) A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
US20250186595A1 (en) A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
Kaplonek Improving the Immunoprotective Effect of Carbohydrate Vaccine Against Bacterial Pneumonia
Martin The Synthesis and Biological Evaluation of Anti-Adhesion Glycoconjugates Against Opportunistic Pathogenic Candida albicans
De Jesus et al. Carbohydrate‐Based Antifungal Vaccines
HK1069125A1 (en) Beta-glucan-based anti-fungal vaccines
HK1069125B (en) Beta-glucan-based anti-fungal vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200821

CF01 Termination of patent right due to non-payment of annual fee